![]() The goal of asthma management is to reach the optimal control of respiratory symptoms, limiting their impacts on daily activity and quality of life. ![]() Adherence to the application was better than that for rhinitis, but it needs to be improved. VAS asthma appears to be an interesting patient-reported outcome highly correlated with dyspnea and impacts on work. MASK-air ® can be used in patients with severe asthma. Highly significant correlations were found for the VAS for asthma, and other patients reported VASs for work, dyspnea, sleep, and rhinitis. Five patients had over 90% well-controlled days, four had well- or moderately controlled asthma (with up to 20% uncontrolled days), one patient had moderately controlled asthma with approximately 20% uncontrolled days, and one patient had 80% uncontrolled days. Highly variably trends were found for the VAS for asthma. There was no correlation between application and medication adherence. ![]() The average application adherence was 51.8% (range: 19.7–98.9%). ![]() Thirteen patients reported on 1229 days of MASK-air ® use. Adherence to MASK-air ® and to the asthma treatment was also checked. The evolution of the visual analogue scales (VAS) for asthma, shortness of breath, rhinitis, conjunctivitis, work, and sleep was monitored using MASK-air ®. Treatment of the patients was not changed based on the application results. Severe asthmatics were proposed to use the MASK-air ® application for 6 months, along with best practice treatment. We explored whether the MASK-air ® application is applicable to patients with severe asthma. MASK-air ®, a good practice of the DG Santé, has been fully validated in allergic rhinitis, but little is known about its applicability to asthmatics. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |